EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Long-Term Evolution of Treatment Outcomes with Once-Daily Ciclosporin A 0.1% Cationic Emulsion in Patients with Dry Eye Disease and Severe Keratitis

Andrea Leonardi, Pasquale Aragona, Maite Sainz de la Maza, Aleksei Seleznev, Edward Wylegala, Edoardo Villani, Christophe Baudouin, Study Investigators

Ophthalmology and Therapy · 2026-07 · 15 (7) · 2413-2429

DOI: 10.1007/s40123-026-01411-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Ophthalmology and Therapy, online erschienen am 12.06.2026. Verfasst von Andrea Leonardi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Ophthalmology Unit, Department of Neuroscience, University of Padua, Via VIII Febbraio, 2, 35122, Padua, PD, Italy. andrea.leonardi@unipd.it. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Santen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: A 3-year multicenter trial was conducted to examine safety/tolerability and potential symptom relief delays following ocular sign improvement in patients with dry eye disease (DED) and severe keratitis using once-daily ciclosporin A (CsA) 0.1% cationic emulsion (CE). METHODS: Adult patients with DED and corneal fluorescein staining (CFS) graded ≥ 3 (modified Oxford scale) received open-label CsA 0.1% CE for 12 months. Patients achieving ≥ 2-grade CFS reduction at month 12 were randomized 3:2 to CsA 0.1% CE or vehicle during months 12-36. Incidence and onset of ocular surface complications and adverse events (AEs) were reported. Spearman's correlation coefficient (SCC) calculations examined any relationship between CFS and symptom assessment in dry eye (SANDE) changes. RESULTS: Overall, 336 participants received open-label CsA 0.1% CE. Mean (standard deviation) age was 59.4 (13.4) years and the majority were female (86.0%) and white (94.6%). In total, 279 (83%) demonstrated ≥ 2-grade CFS reductions and 245 were randomized at month 12. Ocular complications (infections; 3-6-line visual acuity reduction) occurred in 3.2% (n = 11; CsA 0.1% CE; open-label period), 4.7% (n = 7; CsA 0.1% CE; randomized period), and 3.1% (n = 3; vehicle). Median onset was 5.9 (open-label period), 8.2 (CsA 0.1% CE; randomized period), and 6.3 months (vehicle). SCC values comparing month 3 CFS change with SANDE reductions at months 3, 6, 9, and 12 were 0.169, 0.245, 0.274, and 0.178, respectively, and indicated a 3-6-month delay in symptom improvement. Non-serious ocular treatment-related AEs occurred in 62 open-label participants and in 5 (CsA 0.1% CE) and 4 (vehicle) randomized patients. CONCLUSIONS: Once-daily CsA 0.1% CE was well tolerated with low ocular surface complication rates through month 36 in adults with DED. Symptom relief may be delayed by 3-6 months following CFS improvement. CLINICAL TRIAL NUMBER: NCT04144413; EudraCT Number: 2017-002660-41.

Schlagwörter

Stichwörter der Autor:innen

CFSCiclosporin A 0.1% cationic emulsionCorneal fluorescein stainingCsADry eye diseaseSANDE

Autor:innen und Institutionen

  • Ophthalmology Unit, Department of Neuroscience, University of Padua, Via VIII Febbraio, 2, 35122, Padua, PD, Italy. andrea.leonardi@unipd.it.
  • Ophthalmology Unit, Department of Biomedical Sciences, University of Messina, Messina, Italy.
  • Clinical Institute of Ophthalmology, Hospital Clinic de Barcelona, Barcelona, Spain.
  • Ivanovo State Medical University, Ivanovo, Russia.
  • Ivanovo Regional Clinical Hospital, Ivanovo, Russia.
  • Department and Clinic of Ophthalmology at the Medical, University of Silesia (SUM) Medical Centre Wylegala, Katowice, Poland.

Förderung

  • Santen

Zitieren

APA

Leonardi, A., Aragona, P., Sainz de la Maza, M., Seleznev, A., Wylegala, E., Villani, E., Baudouin, C., & Study Investigators (2026). Long-Term Evolution of Treatment Outcomes with Once-Daily Ciclosporin A 0.1% Cationic Emulsion in Patients with Dry Eye Disease and Severe Keratitis. Ophthalmology and Therapy, 15(7), 2413-2429. https://doi.org/10.1007/s40123-026-01411-3

Vancouver

Leonardi A, Aragona P, Sainz de la Maza M, Seleznev A, Wylegala E, Villani E, et al. Long-Term Evolution of Treatment Outcomes with Once-Daily Ciclosporin A 0.1% Cationic Emulsion in Patients with Dry Eye Disease and Severe Keratitis. Ophthalmology and Therapy. 2026;15(7):2413-2429. doi:10.1007/s40123-026-01411-3

BibTeX
@article{Leonardi2026,
  author = {Leonardi, Andrea and Aragona, Pasquale and Sainz de la Maza, Maite and Seleznev, Aleksei and Wylegala, Edward and Villani, Edoardo and Baudouin, Christophe and Study Investigators, Study Investigators},
  title = {Long-Term Evolution of Treatment Outcomes with Once-Daily Ciclosporin A 0.1% Cationic Emulsion in Patients with Dry Eye Disease and Severe Keratitis},
  journal = {Ophthalmology and Therapy},
  year = {2026},
  volume = {15},
  number = {7},
  pages = {2413--2429},
  doi = {10.1007/s40123-026-01411-3}
}
Kostenlos starten →